MXPA03009720A - USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. - Google Patents

USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Info

Publication number
MXPA03009720A
MXPA03009720A MXPA03009720A MXPA03009720A MXPA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
against benign
Prior art date
Application number
MXPA03009720A
Other languages
English (en)
Spanish (es)
Inventor
Anthony P D W Ford
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03009720A publication Critical patent/MXPA03009720A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03009720A 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. MXPA03009720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
PCT/EP2002/001085 WO2002085458A2 (en) 2001-04-23 2002-02-02 Use of nk-1 receptor antagonists against benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
MXPA03009720A true MXPA03009720A (es) 2004-01-29

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009720A MXPA03009720A (es) 2001-04-23 2002-02-02 USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.

Country Status (17)

Country Link
US (1) US20030004157A1 (https=)
EP (1) EP1385577B1 (https=)
JP (1) JP4146730B2 (https=)
KR (1) KR100599134B1 (https=)
CN (1) CN100398106C (https=)
AR (1) AR035935A1 (https=)
AT (1) ATE323531T1 (https=)
AU (1) AU2002250876B2 (https=)
BR (1) BR0209151A (https=)
CA (1) CA2444395C (https=)
DE (1) DE60210760T2 (https=)
DK (1) DK1385577T3 (https=)
ES (1) ES2261657T3 (https=)
MX (1) MXPA03009720A (https=)
PT (1) PT1385577E (https=)
WO (1) WO2002085458A2 (https=)
ZA (1) ZA200308110B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
SI1643998T1 (sl) * 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ.ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2010106988A1 (ja) 2009-03-17 2010-09-23 第一三共株式会社 アミド誘導体
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
AU2019215801B2 (en) * 2018-02-02 2024-09-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
IL134155A0 (en) * 1997-08-06 2001-04-30 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists
CN1272842A (zh) * 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
ZA200308110B (en) 2005-03-30
CA2444395C (en) 2010-12-21
WO2002085458A2 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
AR035935A1 (es) 2004-07-28
JP4146730B2 (ja) 2008-09-10
DE60210760T2 (de) 2006-11-23
ES2261657T3 (es) 2006-11-16
DK1385577T3 (da) 2006-08-21
CA2444395A1 (en) 2002-10-31
US20030004157A1 (en) 2003-01-02
ATE323531T1 (de) 2006-05-15
PT1385577E (pt) 2006-08-31
DE60210760D1 (de) 2006-05-24
KR100599134B1 (ko) 2006-07-12
BR0209151A (pt) 2004-07-13
CN1503684A (zh) 2004-06-09
EP1385577A2 (en) 2004-02-04
AU2002250876B2 (en) 2005-03-03
KR20040007503A (ko) 2004-01-24
CN100398106C (zh) 2008-07-02
WO2002085458A3 (en) 2003-10-30
EP1385577B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
MXPA03009720A (es) USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
ZA200401214B (en) Synthesis of poly-alpha olefin and use thereof.
HUP0302544A3 (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
ITMI20002076A0 (it) Procedimento ed apparecchiatura per il controllo della miscelazione di bevande.
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
AU9684401A (en) Hedgehog antagonists, methods and uses related thereto
SI1455785T1 (sl) Substituirani 2-tio-3,5-diciano-4-fenil-6-aminopiridini in njihova uporaba
AU2002367424A1 (en) Androgen receptor antagonists
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
IL158701A0 (en) Novel use of nk3 receptor antagonist
AU2002365655A1 (en) 5-ht7 receptor antagonists
EP1359915A4 (en) UROTENSIN-II RECEPTOR ANTAGONISTS
DK1296961T3 (da) 1,4-diazepan-2,5-dionderivater og anvendelse deraf som NK-1-receptorantagonister
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
MXPA03003892A (es) Antagonistas del receptor bombesin.
EP1351687A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
MXPA03004414A (es) Natagonistas del receptor bombesin.
ZA200403530B (en) Chemokine receptor antagonists and methods of use thereof.
MXPA03004341A (es) Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina.
IL137953A0 (en) Phthalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
MXPA03006970A (es) Nuevo uso de iloperidona.
ZA200401146B (en) Agonists and antagonists of 5HT3-like receptor of invertebrates as pesticides.
GB0600493D0 (en) Protein markers for human benign prostatic hyperplasia(BPH)
DK1056720T3 (da) Phtalimido-arylpiperaziner som alfa-1A-receptorantagonister, der er nyttige til behandling af godartet prostatahyperplasi

Legal Events

Date Code Title Description
FG Grant or registration